Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
PDS Biotechnology Corporation (DE:EU6)
MUNICH:EU6
PDS Biotechnology (EU6) Stock Price & Analysis
0 Followers
EU6 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€2.60 - €9.15
Previous Close€2.6
Volume0.00
Average Volume (3M)1.15K
Market Cap
€93.50M
Enterprise Value€62.65M
Total Cash (Recent Filing)$56.60M
Total Debt (Recent Filing)$23.85M
Price to Earnings (P/E)N/A
Beta1.12
Next Earnings
May 14, 2024EPS Estimate
-€0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. Volume1,146
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-1.60
Forecast
1Y Price Target
€15.30Price Target Upside488.60% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
PDS Biotechnology News
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessClinical trial results revealing a durable survival rate and high safety profile for PDS Biotechnology's treatments may increase investor confidence in the company's potential to meet regulatory approvals and become a standard in immunotherapy.
Deal SignificanceThe strategic deal emphasizing tumor-targeted IL-12 delivery showcases the potential of PDS Biotechnology's focus on Triplet Therapy in HNSCC, aligning with recent industry trends and underscoring the company's innovative approach.
Financial StabilityPDS Biotechnology's strong financial position, with significant cash reserves, indicates a solid foundation for sustaining operations and advancing its late-stage development programs, potentially leading to growth and value creation for shareholders.
Bears Say
Capital ConcernsWith a current cash balance of $60.6M, the company might need to explore partnership collaborations for Phase III development or consider various financing avenues to reduce shareholder dilution.
Drug Development DelaysA delay to the start of a registration-enabling program for PDSB's leading immunotherapy is acknowledged, which has been somewhat reflected in the company's stock underperformance.
Financial PerformancePDSB posted a 2Q net loss of $(0.37)/share, in line with analyst's forecasts.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00%
Insiders
0.00% Mutual Funds
0.99% Other Institutional Investors
99.01% Public Companies and
Individual Investors
EU6 FAQ
What was PDS Biotechnology Corporation’s price range in the past 12 months?
PDS Biotechnology Corporation lowest stock price was €2.60 and its highest was €9.15 in the past 12 months.
What is PDS Biotechnology Corporation’s market cap?
Currently, no data Available
When is PDS Biotechnology Corporation’s upcoming earnings report date?
PDS Biotechnology Corporation’s upcoming earnings report date is May 14, 2024 which is in 25 days.
How were PDS Biotechnology Corporation’s earnings last quarter?
PDS Biotechnology Corporation released its earnings results on Mar 27, 2024. The company reported -€0.33 earnings per share for the quarter, beating the consensus estimate of -€0.414 by €0.084.
Is PDS Biotechnology Corporation overvalued?
According to Wall Street analysts PDS Biotechnology Corporation’s price is currently Undervalued.
Does PDS Biotechnology Corporation pay dividends?
PDS Biotechnology Corporation does not currently pay dividends.
What is PDS Biotechnology Corporation’s EPS estimate?
PDS Biotechnology Corporation’s EPS estimate is -€0.35.
How many shares outstanding does PDS Biotechnology Corporation have?
Currently, no data Available
What happened to PDS Biotechnology Corporation’s price movement after its last earnings report?
PDS Biotechnology Corporation reported an EPS of -€0.33 in its last earnings report, beating expectations of -€0.414. Following the earnings report the stock price went down -8.42%.
Which hedge fund is a major shareholder of PDS Biotechnology Corporation?
Among the largest hedge funds holding PDS Biotechnology Corporation’s share is New Leaf Venture Partners, L.L.C.. It holds PDS Biotechnology Corporation’s shares valued at N/A.
---
PDS Biotechnology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€15.30 (488.60% Upside)
€15.30 (488.60% Upside)
Blogger Sentiment
Bullish
DE:EU6 Sentiment 100%
Sector Average 70%
Sector Average 70%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-60.23%
12-Months-Change
Fundamentals
Return on Equity
-122.46%
Trailing 12-Months
Asset Growth
-22.88%
Trailing 12-Months
Company Description
PDS Biotechnology Corporation
PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded on March 15, 2019 and is headquartered in Berkeley Heights, NJ.
---
EU6 Earnings Call
Q4 2024
0:00 / 0:00
---
EU6 Stock 12 Months Forecast
Average Price Target
€15.30
▲(488.60% Upside)
Technical Analysis
Best Analysts Covering EU6
1 Year
1 Year Success Rate
6/13 ratings generated profit
1 Year Average Return
+12.46%
reiterated a buy rating 5 months ago
Copying Leland Gershell's trades and holding each position for 1 Year would result in 46.15% of your transactions generating a profit, with an average return of +12.46% per trade.
---